Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)

This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.

Trial Details

NCT ID
NCT07936266
Phase
PHASE1
Sponsor
Sunil G. Iyer
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Asciminib
  • Inotuzumab ozogamicin
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Chicago, Illinois, United States|41.85003,-87.65005
  • New York, New York, United States|40.71427,-74.00597
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Documented and confirmed CD22+ R/R Ph+ B-ALL according to the World Health Organization (WHO) classification
  • Relapsed ALL is defined as the detection of ≥ 5% blasts in the bone marrow with or without non-central nervous system (CNS) extramedullary disease
  • Refractory ALL is defined as the failure to obtain a CRc after at least two courses of intensive induction or immunotherapy such as blinatumomab, o…
  • Disease must be positive for Ph (p190 or p210 transcript) by cytogenetics or PCR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →